Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

evobrutinib

- PMLiVE

Currencies hit Merck Serono sales but firm says it is ‘on course’

Overall groups sales down to €2.84bn for second quarter of 2013

Biogen Idec building

Biogen Idec’s long-acting beta interferon moves ahead in MS

US and EU accept filings for long-acting multiple sclerosis drug Plegridy

Biogen Idec building

Biogen Idec signs brain research deal with Edinburgh University

Will identify potential treatments for multiple sclerosis and motor neurone disease

- PMLiVE

Almirall launches Sativex in Italy

Brings cannabis-based drug for multiple sclerosis spasticity to market

- PMLiVE

Merck Serono pushes into immunotherapies for cancer

Pharma company sets up dedicated R&D unit

- PMLiVE

GSK buys rights to MorphoSys’ arthritis antibody

Pharma company will pay up €445m to develop and commercialise MOR103

- PMLiVE

Merck KGaA to research cancer drug with Chinese biotech

German pharma firm teams up with BeiGene on BRAF inhibitor

Biogen Idec building

Biogen Idec says Tecfidera launch delayed in Europe

Company wants to resolve patent and regulatory data protection issues for oral MS drug

- PMLiVE

Merck KGaA forges clinical alliance with Quintiles

CRO becomes sole outsourcing partner for pharma company

- PMLiVE

Merck KGaA to meet 2014 financial targets one year early

But continued growth of Rebif under threat from new oral MS drugs

Biogen Idec building

Biogen Idec’s Tecfidera approved in US

Green light from FDA closely follows MS drug's European approval

- PMLiVE

CHMP backs oral MS drugs from Sanofi, Biogen Idec

Tecfidera and Aubagio recommended for use in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links